Mitsui Kinzoku Stock Surges to Record High After Profit Forecast Upgrade and Dividend Increase 
Sachem Head Boosts Warner Bros. Discovery Stake Amid Netflix Deal and Paramount Bid 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Valero Energy Expands Venezuelan Crude Imports as U.S. Sanctions Ease 
Bank of America CEO Brian Moynihan’s 2025 Compensation Rises 17% to $41 Million Amid Strong Profit Growth 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
BlueScope Steel Forecasts Stronger Second-Half Earnings, Shares Rise Above Rejected Buyout Offer 
Senators Urge CFIUS Review of UAE Investment in Trump-Linked Crypto Firm World Liberty Financial 
Disney Issues Cease-and-Desist to ByteDance Over Alleged AI Copyright Infringement 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Lockheed Martin Secures $101M in U.S. Defense Contracts for AEGIS, F-35, and Missile Systems 
Bain Capital Secures RBI Approval to Acquire Up to 41.7% Stake in Manappuram Finance 
Macquarie-Led Consortium to Acquire Qube Holdings in A$11.7 Billion Deal 
Anduril Eyes $60 Billion Valuation in New Funding Round to Expand Defense Manufacturing and Autonomous Fighter Jet Development 
RICHLAND, Wash., April 26, 2018 -- IsoRay, Inc. (the “Company”) (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological cancers, today announced that it will host a teleconference to discuss third quarter fiscal 2018 financial results on Thursday, May 3, 2018, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the third quarter of fiscal 2018 ended March 31, 2018, immediately after the close of the market on May 3, 2018.
Interested parties are asked to dial-in approximately 10 minutes before the call begins at the following numbers:
U.S. Participants: (877) 270-2148
International Participants: + 1-412-902-6510
Participant Passcode: 10119919
The earnings release and a replay of the call will be available through the Investor Relations section of the Company’s website: https://isoray.com/about/investors/presentations/. A replay of the call will be available for one week beginning at approximately 10:00 p.m. Eastern Time on May 3, 2018. The playback can be accessed by dialing (877) 344-7529 (U.S.) and +1-412-317-0088 (International). The passcode is 10119919.
About IsoRay, Inc.
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com. Join us on Facebook/IsoRay. Follow us on Twitter @IsoRay.
Contacts: IsoRay, Inc. [email protected] (509) 375-1202 Investors: Stephanie Prince, Managing Director PCG Advisory Group [email protected] (646) 762-4518
